News

Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, has been approved to treat adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after

The companies will focus on a single G protein-coupled receptor (GPCR) nominated by Daiichi Sankyo that plays a crucial role in relieving pain. Under the terms of the

No new safety signals or unexpected safety findings were seen in this long-term safety study. The profile of observed adverse events (AEs) was similar to that reported for

Kisqali, which is a selective cyclin-dependent kinase inhibitor, has been approved as initial endocrine-based therapy to treat postmenopausal women with hormone receptor positive and human epidermal growth factor

Synairgen is collaboraing with Australian firm Pharmaxis on the program which will target scar tissue that inhibits breathing in sufferers of idiopathic pulmonary fibrosis (IPF), a lethal lung condition. If

Orphan drug designation is granted by the FDA to investigational compounds intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect

The round includes participation by additional new investors RA Capital Management and Rock Springs Capital as well as existing investors. Proceeds from the financing will be used to

Servier, which took the responsibility of the CALM Phase 1 study, purchased exclusive rights of UCART19 from Cellectis in 2015.  Last August, the CALM study was started in

Key highlights include: Pelican was the recipient of a highly competitive $15.2m New Company Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT), which